Pseudoephedrine
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
- Pseudoephedrine
- Pseudoephedrine: From Seasonal Allergic Rhinitis with Nasal Congestion to Nasal Cavity Disease
Pseudoephedrine: From Seasonal Allergic Rhinitis with Nasal Congestion to Nasal Cavity Disease
One-Sentence Summary
Pseudoephedrine is a decongestant, originally authorised in the EU (as the combination product Aerinaze) for the symptomatic treatment of seasonal allergic rhinitis accompanied by nasal congestion. The TxGNN model predicts it may be useful for nasal cavity disease, but there are no registered clinical trials and only 7 publications, most of them preclinical or reviews, so the support is limited.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L4 |
| EU Market Status | Cancelled only (no currently valid authorisation) |
| Number of Authorizations | 1 (cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, pseudoephedrine is a sympathomimetic that stimulates alpha-adrenergic receptors in the nasal mucosa. This causes vasoconstriction and reduces mucosal swelling, which relieves nasal congestion.
The original indication (nasal congestion in seasonal allergic rhinitis) and the predicted indication (nasal cavity disease) overlap heavily. Congestion is a common symptom across many nasal conditions. The prediction is therefore better seen as an extension of the existing label than as a truly new use. The 99.75% score is a computational prediction only and is not itself clinical evidence.
Two other predictions were also generated. Acute laryngopharyngitis (score 99.73%) has no supporting trials or literature, and pseudoephedrine has no known anti-inflammatory or anti-infective action relevant to it. Allergic urticaria (score 99.14%) is supported only by papers on antihistamines, not pseudoephedrine, which does not block histamine H1 receptors. Both are rated L5 and Hold.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11345158 | 2001 | Clinical pharmacology study | Am J Rhinol | Compared oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine on nasal cavity dimensions using acoustic rhinometry |
| 22794679 | 2012 | Review | Allergy Asthma Proc | Overview of nonallergic rhinitis, a group of disorders with nasal congestion, rhinorrhea and sneezing |
| 19769798 | 2009 | Preclinical (cat) | Am J Rhinol Allergy | Loratadine plus montelukast decongestion in a feline model; d-pseudoephedrine also tested with and without desloratadine |
| 12962193 | 2003 | Preclinical (dog) | Am J Rhinol | Dog model of allergic nasal congestion in ragweed-sensitised animals |
| 12387934 | 2002 | Preclinical (dog) | J Pharmacol Toxicol Methods | Pharmacological characterisation of a chronic dog model of nasal congestion |
| 11895194 | 2002 | Preclinical (dog) | Am J Rhinol | Acoustic rhinometry dog model for studying nasal congestion |
| 24492651 | 2014 | Preclinical animal study | J Pharmacol Exp Ther | Selective α2c-adrenergic agonists in nasal congestion models (not specific to pseudoephedrine) |
EU Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| EMEA/H/C/000772 (cancelled) | Aerinaze | Not specified | Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion. |
Safety Considerations
- Disease-related cautions from the knowledge graph (not label text): the TxGNN knowledge graph links pseudoephedrine to contraindication edges for many conditions. Main groups:
- Cardiovascular and cerebrovascular: hypertension, congestive heart failure, coronary artery disease, stroke and cerebrovascular disorders
- Metabolic and endocrine: diabetes mellitus, diabetic ketoacidosis, hypothyroidism
- Liver, kidney and gastrointestinal: liver disease and failure, kidney disease, peptic and gastric ulcer, pancreatitis, inflammatory bowel disease
- Other: epilepsy, COPD, benign prostatic hyperplasia, substance abuse or dependence
- Drug Interactions: 150 interactions were identified. The sample reviewed included mostly moderate-level interactions with antidiabetic agents (e.g. acarbose, glimepiride, glipizide, glyburide, insulins, canagliflozin, dapagliflozin, empagliflozin, exenatide, dulaglutide), and with diethylpropion. Interaction with ascorbic acid is minor.
Please refer to the SmPC for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for nasal cavity disease is mechanistically plausible but largely duplicates the existing label. No clinical trials exist, and the literature is mainly preclinical or review material. The EU authorisation is cancelled, and label-based safety information is unavailable. The other two predicted indications have no direct supporting evidence.
To proceed, the following is needed:
- The SmPC warnings and contraindications, to allow safety screening
- Mechanism of action data from DrugBank
- Clinical studies of pseudoephedrine in specific nasal cavity disorders (for example nonallergic rhinitis)
- A defined target condition and formulation, given the cancelled authorisation
- A cardiovascular and metabolic safety review, given the many knowledge-graph contraindications and antidiabetic interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.